bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2024-69-1-112-120bloodjour-521Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCASE REPORTSТрансформация лимфомы маргинальной зоны в диффузную В-крупноклеточную лимфомуTransformation of indolent lymphomas into diffuse large B-cell lymphomahttps://orcid.org/0000-0003-4263-8275МагомедоваА. У.MagomedovaA. U.

Магомедова Аминат Умарасхабовна, доктор медицинских наук, ведущий научный сотрудник отделения лимфатических опухолей с блоком трансплантации гемопоэтических стволовых клеток и дневным стационаром 

125167, Москва

Aminat U. Magomedova, Dr. Sci. (Med.), Leading Researcher of the Department of Lymphatic Tumors with a hematopoietic stem cell transplantation unit and a day hospital

125167, Moscow

   

maminat@mail.ruhttps://orcid.org/0000-0002-1082-8659КовригинаА. М.KovriginaA. M.

Ковригина Алла Михайловна, доктор биологических наук, заведующая патологоанатомическим отделением

125167, Москва

Alla M. Kovrigina, Dr. Sci. (Biol.), Head of the Pathology Department

125167, Moscow

kovrigina.alla@gmail.comhttps://orcid.org/0000-0002-5522-7531МангасароваЯ. К.MangasarovaYa. K.

Мангасарова Яна Константиновна, кандидат медицинских наук, заведующая отделением химиотерапии лимфатических опухолей с блоком трансплантации костного мозга и гемопоэтических стволовых клеток с дневным стационаром

125167, Москва

Yana K. Mangasarova, Cand. Sci. (Med.), Head of the Department of Chemotherapy of Lymphatic Tumors with Bone Marrow and Hematopoietic Stem Cell Transplantation Unit

125167, Moscow

v.k.jana@mail.ruhttps://orcid.org/0000-0001-9086-8521КравченкоС. К.KravchenkoS. K.

Кравченко Сергей Кириллович, кандидат медицинских наук, заведующий отделением химиотерапии лимфопролиферативных заболеваний

125167, Москва

Sergey K. Kravchenko, Cand. Sci. (Med.), Head of the Department of Chemotherapy of Lymphoproliferative Diseases

125167, Moscow

https://orcid.org/0000-0003-3914-8611НикулинаЕ. Е.NikulinaE. E.

Никулина Елена Евгеньевна, научный сотрудник лаборатории молекулярной гематологии 

125167, Москва

Elena E. Nikulina, Research associate Laboratory of Molecular Hematology

125167, Moscow

   

nikulina.e@blood.ruhttps://orcid.org/0000-0003-1613-652XОбуховаТ. Н.ObukhovaT. N.

Обухова Татьяна Никифоровна, кандидат медицинских наук, заведующая лабораторией кариологии

125167, Москва

Tatyana N. Obukhova, Cand. Sci. (Med.), Head of the Karyology Laboratory

125167, Moscow

   

obukhova_t@mail.ruhttps://orcid.org/0000-0002-2639-7419ЗвонковЕ. Е.ZvonkovE. E.

Звонков Евгений Евгеньевич, доктор медицинских наук, заведующий отделением гематологии и химиотерапии лимфом с блоком трансплантации костного мозга и гемопоэтических стволовых клеток

125167, Москва

Evgeny E. Zvonkov, Dr. Sci. (Med.), Head of the Department of Hematology and Chemotherapy of Lymphomas with Bone Marrow and Hematopoietic Stem Cell Transplantation Unit

125167, Moscow

ФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской ФедерацииРоссияNational Medical Research Center for HematologyRussian Federation202419032024691112120Copyright © Магомедова А.У., Ковригина А.М., Мангасарова Я.К., Кравченко С.К., Никулина Е.Е., Обухова Т.Н., Звонков Е.Е., 20242024Магомедова А.У., Ковригина А.М., Мангасарова Я.К., Кравченко С.К., Никулина Е.Е., Обухова Т.Н., Звонков Е.Е.Magomedova A.U., Kovrigina A.M., Mangasarova Y.K., Kravchenko S.K., Nikulina E.E., Obukhova T.N., Zvonkov E.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/521Введение

Введение. Лимфома из клеток маргинальной зоны в ряде случаев может проявлять себя только на этапе гистологической трансформации в агрессивные лимфомы, в том числе в диффузную В-крупноклеточную лимфому (ДВККЛ). Цель — представить клиническое наблюдение трансформированной в ДВККЛ (тДВККЛ) на момент диагностики лимфомы из клеток маргинальной зоны.

Основные сведения

Основные сведения. Приведено клиническое наблюдение рецидива ДВККЛ образования подчелюстной области, которое было удалено полностью, больная находилась под наблюдением 11 лет без лечения. Во время рецидива было выявлено образование нижней доли правого легкого с SUV max до 19,27 размерами 81×43×88 мм. Выполнена атипичная резекция нижней доли правого легкого. По данным гистологического и иммуногистохимического исследований установлен диагноз «лимфома из клеток маргинальной зоны с трансформацией в ДВККЛ». При исследовании с помощью полимеразной цепной реакции доказана идентичность клона индолентной и возникшей агрессивной В-клеточной лимфомы. Проведена терапия по программе «R-CHOP+леналидомид», достигнута полная ремиссия заболевания.

Introduction

Introduction. Lymphoma from cells of the marginal zone in some cases can manifest itself only at the stage of histological transformation into aggressive lymphomas, including diffuse large B-cell lymphoma (DLBCL).

Aim

Aim: to present a clinical observation of lymphoma transformed at the time of diagnosis from marginal zone cells to DLBCL.

Main findings

Main findings. A case report of relapsed DLBCL in the submandibular area is presented, which was observed for 11 years without treatment. At the time of relapse, a 81×43×88 mm mass in the lower lobe of the right lung with SUV max up to 19.27 was identified. Atypical resection of the lower lobe of the right lung was performed. Based on histology and immunohistochemistry, a diagnosis of DLBCL transformed from marginal zone B-cell lymphoma was established, with PCR confirming the identity of the clone of indolent and aggressive B-cell lymphoma. The patient received R-CHOP plus lenalidomide therapy and achieved complete remission.

   

лимфома из клеток маргинальной зоныгистологическая трансформациярецидивдиффузная В-крупноклеточная лимфомаmarginal zone B-cell lymphomahistological transformationdiffuse large B-cell lymphomarelapseindolent lymphomasReferencesCampo E., Pileri S.A., Jaffe E.S., et al. Nodal marginal zone lymphoma. WHO classifi cation of Tumors of Haematopoietic and Lymphoid Tissues. 2017; 263–5.Campo E., Pileri S.A., Jaffe E.S., et al. Nodal marginal zone lymphoma. WHO classifi cation of Tumors of Haematopoietic and Lymphoid Tissues. 2017; 263–5.Cook J.R., Isaacson P.G., Chott A. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) WHO Classifi cation of Tumors of Haematopoietic and Lymphoid Tissues. 2017; 259–62.Cook J.R., Isaacson P.G., Chott A. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) WHO Classifi cation of Tumors of Haematopoietic and Lymphoid Tissues. 2017; 259–62.Piris M.A., Isaacson P.G., Swerdlow S.H., et al. Splenic marginal zone lymphoma. WHO classifi cation of Tumors of Haematopoietic and Lymphoid Tissues. 2017; 223–6.Piris M.A., Isaacson P.G., Swerdlow S.H., et al. Splenic marginal zone lymphoma. WHO classifi cation of Tumors of Haematopoietic and Lymphoid Tissues. 2017; 223–6.Alaggio R., Amador C., Anagnostopoulos I., et al. The 5th edition of the World Health Organization Classifi cation of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36: 1720–48. DOI: 10.1038/s41375-02201620-2.Alaggio R., Amador C., Anagnostopoulos I., et al. The 5th edition of the World Health Organization Classifi cation of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36: 1720–48. DOI: 10.1038/s41375-02201620-2.Dungarwalla M., Appiah-Cubi S, Kulkarni S., et al. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation infl uences response to therapy and prognosis. Br J Haematol. 2008; 143(1): 71–4. DOI: 10.1111/j.1365-2141.2008.07301.x.Dungarwalla M., Appiah-Cubi S, Kulkarni S., et al. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation infl uences response to therapy and prognosis. Br J Haematol. 2008; 143(1): 71–4. DOI: 10.1111/j.1365-2141.2008.07301.x.Conconi A, Franceschetti S, Aprile von Hohenstaufen K., et al. Histologic transformation in marginal zone lymphomas. Ann Oncol. 2015; 26(11): 2329–35. DOI: 10.1093/annonc/mdv368.Conconi A, Franceschetti S, Aprile von Hohenstaufen K., et al. Histologic transformation in marginal zone lymphomas. Ann Oncol. 2015; 26(11): 2329–35. DOI: 10.1093/annonc/mdv368.Berger F., Felman P., Thieblemont C., et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000; 95(6): 1950–6.Berger F., Felman P., Thieblemont C., et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000; 95(6): 1950–6.Du Y, Wang Y, Li Q., et al. Transformation to diffuse large B-cell lymphoma and its impact on survival in patients with marginal zone lymphoma: A populationbased study. Int J Cancer. 2024; 154(6): 969–78. DOI: 10.1002/ijc.34773.Du Y, Wang Y, Li Q., et al. Transformation to diffuse large B-cell lymphoma and its impact on survival in patients with marginal zone lymphoma: A populationbased study. Int J Cancer. 2024; 154(6): 969–78. DOI: 10.1002/ijc.34773.Kiesewetter B., Lamm W., Dolak W., et al. Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. Br J Haematol. 2019; 186: 448–59. DOI: 10.1111/bjh.15953.Kiesewetter B., Lamm W., Dolak W., et al. Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. Br J Haematol. 2019; 186: 448–59. DOI: 10.1111/bjh.15953.Maeshima A.M., Taniguchi H., Toyoda K., et al. Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. Br J Haematol. 2016; 174: 923–31. DOI: 10.1111/bjh.14153.Maeshima A.M., Taniguchi H., Toyoda K., et al. Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. Br J Haematol. 2016; 174: 923–31. DOI: 10.1111/bjh.14153.Magomedova A., Kravchenko S., Misyurina A., et al. Multicenter Randomized Controlled (Comparative) Open Prospective Study to Evaluate The Effi cacy of The R-DA-EPOCH-21 And R-mNHL-BFM-90 ± Autologous Hematopoietic Stem Cell Transplantation Programs in Untreated Patients With De Novo Diffuse BCell Large Cell Lymphoma With Signs of Poor Prognosis — DLBCL-2015 Protocol. Arch Clin Trials. 2022; 2(3): 1–10. DOI:10.33425/2768-4598.1025.Magomedova A., Kravchenko S., Misyurina A., et al. Multicenter Randomized Controlled (Comparative) Open Prospective Study to Evaluate The Effi cacy of The R-DA-EPOCH-21 And R-mNHL-BFM-90 ± Autologous Hematopoietic Stem Cell Transplantation Programs in Untreated Patients With De Novo Diffuse BCell Large Cell Lymphoma With Signs of Poor Prognosis — DLBCL-2015 Protocol. Arch Clin Trials. 2022; 2(3): 1–10. DOI:10.33425/2768-4598.1025.Ghesquieres H., Berger F, Felman P., et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol. 2006; 24(33): 5234–41. DOI: 10.1200/JCO.2006.07.5671.Ghesquieres H., Berger F, Felman P., et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol. 2006; 24(33): 5234–41. DOI: 10.1200/JCO.2006.07.5671.Lenglet J., Traulle C., Mounier N., et al. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as fi rst-line treatment. Leuk Lymphoma. 2014; 55(8): 1854–60. DOI: 10.3109/10428194.2013.861067.Lenglet J., Traulle C., Mounier N., et al. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as fi rst-line treatment. Leuk Lymphoma. 2014; 55(8): 1854–60. DOI: 10.3109/10428194.2013.861067.Wright G.W., Huang D.W., Phelan J.D., et al. A Probabilistic Classifi cation Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications J. Cancer Cell. 2020; 37(4): 551–68.e14. DOI: 10.1016/j.ccell.2020.03.015.Wright G.W., Huang D.W., Phelan J.D., et al. A Probabilistic Classifi cation Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications J. Cancer Cell. 2020; 37(4): 551–68.e14. DOI: 10.1016/j.ccell.2020.03.015.Malecka G., Troen, A., Tierens A., et.al. Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease. Br. J. Haematol. 2018; 183: 838–42. DOI: 10.1111/bjh.15063.Malecka G., Troen, A., Tierens A., et.al. Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease. Br. J. Haematol. 2018; 183: 838–42. DOI: 10.1111/bjh.15063.Singh M., Jackson K.J.L., Wang J.J., et al. Lymphoma driver mutations in the pathogenic evolution of an iconic human autoantibody. Cell. 2020; 180: 878– 94.e19. DOI: 10.1016/j.cell.2020.01.029.Singh M., Jackson K.J.L., Wang J.J., et al. Lymphoma driver mutations in the pathogenic evolution of an iconic human autoantibody. Cell. 2020; 180: 878– 94.e19. DOI: 10.1016/j.cell.2020.01.029.Flossbach L., Antoneag E., Buck M., et al. BCL6 gene rearrangement and protein expression are associated with large cell presentation of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Int. J. Cancer. 2011; 129: 70–7. DOI: 10.1002/ijc.25663.Flossbach L., Antoneag E., Buck M., et al. BCL6 gene rearrangement and protein expression are associated with large cell presentation of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Int. J. Cancer. 2011; 129: 70–7. DOI: 10.1002/ijc.25663.Воробьев А.И. Вопросы клоновой теории лейкозов. Проблемы гематологии. 1965; 2: 14–22.A.Vorobyev A.I. Questions of the clone theory of leukemia. Problems of hematology. 1965; 2: 14–22.A. (In Russian).Traverse-Glehen A., Felman P., Callet-Bauchu E., et al. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology. 2006; 48: 162–73. DOI: 10.1111/j.1365-2559.2005.02309.x.Traverse-Glehen A., Felman P., Callet-Bauchu E., et al. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology. 2006; 48: 162–73. DOI: 10.1111/j.1365-2559.2005.02309.x.Поддубная И.В., Савченко В.Г. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. М.: ООО «Буки Веди», 2016: 48–55.Poddubnaya I.V., Savchenko V.G. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Moscow: Buki Vedi, 2018: 52–7. (In Russian).Leonard J.P, Trneny M., Izutsu K., et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019; 37: 1188–99. DOI: 10.1200/JCO.19.00010.Leonard J.P, Trneny M., Izutsu K., et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019; 37: 1188–99. DOI: 10.1200/JCO.19.00010.

The authors declare that there are no conflicts of interest present.